↓ Skip to main content

Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience

Overview of attention for article published in Molecular Genetics & Genomic Medicine, August 2018
Altmetric Badge

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience
Published in
Molecular Genetics & Genomic Medicine, August 2018
DOI 10.1002/mgg3.453
Pubmed ID
Authors

Kathryn M. Porter, Tia L. Kauffman, Barbara A. Koenig, Katie L. Lewis, Heidi L. Rehm, Carolyn Sue Richards, Natasha T. Strande, Holly K. Tabor, Susan M. Wolf, Yaping Yang, Laura M. Amendola, Danielle R. Azzariti, Jonathan S. Berg, Katie Bergstrom, Leslie G. Biesecker, Sawona Biswas, Kevin M. Bowling, Wendy K. Chung, Ellen W. Clayton, Laura K. Conlin, Gregory M. Cooper, Matthew C. Dulik, Levi A. Garraway, Arezou A. Ghazani, Robert C. Green, Susan M. Hiatt, Seema M. Jamal, Gail P. Jarvik, Katrina A. B. Goddard, Benjamin S. Wilfond, The members of the CSER Actionability and Return of Results Working Group

Abstract

Clinical genome and exome sequencing (CGES) is primarily used to address specific clinical concerns by detecting risk of future disease, clarifying diagnosis, or directing treatment. Additionally, CGES makes possible the disclosure of autosomal recessive and X-linked carrier results as additional secondary findings, and research about the impact of carrier results disclosure in this context is needed. Representatives from 11 projects in the clinical sequencing exploratory research (CSER) consortium collected data from their projects using a structured survey. The survey focused on project characteristics, which variants were offered and/or disclosed to participants as carrier results, methods for carrier results disclosure, and project-specific outcomes. We recorded quantitative responses and report descriptive statistics with the aim of describing the variability in approaches to disclosing carrier results in translational genomics research projects. The proportion of participants with carrier results was related to the number of genes included, ranging from 3% (three genes) to 92% (4,600 genes). Between one and seven results were disclosed to those participants who received any positive result. Most projects offered participants choices about whether to receive some or all of the carrier results. There were a range of approaches to communicate results, and many projects used separate approaches for disclosing positive and negative results. Future translational genomics research projects will need to make decisions regarding whether and how to disclose carrier results. The CSER consortium experience identifies approaches that balance potential participant interest while limiting impact on project resources.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 22%
Student > Postgraduate 3 8%
Student > Doctoral Student 2 6%
Lecturer 2 6%
Other 2 6%
Other 6 17%
Unknown 13 36%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 17%
Medicine and Dentistry 6 17%
Agricultural and Biological Sciences 4 11%
Social Sciences 3 8%
Nursing and Health Professions 2 6%
Other 2 6%
Unknown 13 36%